Posted by Michael Wonder on 30 Mar 2021
Myovant Sciences announces European Medicines Agency validation of marketing authorisation application for relugolix for the treatment of advanced prostate cancer
29 March 2021 - Pfizer has an exclusive option to commercialise relugolix in oncology outside of the U.S. and Canada, excluding certain Asian countries, with a decision expected in the first half of 2021
Myovant Sciences today announced the EMA has validated the marketing authorisation application for relugolix for the treatment of advanced prostate cancer.
